Exploring Efficacy and Predictors of Response to Venetoclax and Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia: A Real‐World Study

This retrospective study aimed to identify molecular predictors of treatment response and survival in 207 newly diagnosed acute myeloid leukemia (AML) patients treated with Venetoclax combined with hypomethylating agents (VEN-HMAs). After one treatment course, the composite complete remission (CR/CRi) rate was 69.6% (144/207), with 70.5% (93/132) of responders achieving minimal residual disease (MRD) negativity. According to the 2017 ELN risk stratification, the CR/CRi rates in the favorable-, intermediate-, and high-risk groups were 77.2%, 64.0%, and 66.6%, respectively. For treatment response, RUNX1-RUNX1T1, FLT3-ITD, and TP53 mutations independently predicted unfavorable to VEN-HMAs therapy. Multivariable analysis identified NRAS and PTPN11 mutations as independent adverse prognostic factors for overall survival, while achievement of CR/CRi after the first treatment course and receiving hematopoietic stem cell transplantation (HSCT) were favorable predictors. Based on molecular status, patients were stratified into three prognostic groups. The median OS was 9.5 months in the TP53-mutant (low-benefit) group and 21 months in the medium-benefit group (TP53 wild-type with FLT3-ITD or K/NRAS mutations). The high-benefit group (wild-type TP53, no FLT3-ITD, and wild-type K/NRAS) had a significantly superior OS (not reached) compared to the others (p < 0.001), while OS between the medium- and low-benefit groups was comparable (p = 0.096). VEN-HMAs therapy is associated with high response rates in this real-world cohort, though treatment response varies substantially by molecular profile. A comprehensive understanding of these influencing factors and the development of refined risk stratification systems require further investigation.

Authors

Institutions

Publication Details

Journal
International Journal of Cancer
Published
2026-11-12
DOI
https://doi.org/10.1002/ijc.70722
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Exploring Efficacy and Predictors of Response to Venetoclax and Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia: A Real‐World Study

Wei Qin, Suning Chen, Zhao Zeng, Xinyu Gao et al.
International Journal of Cancer
Acute Myeloid Leukemia Research
article

Exploring Efficacy and Predictors of Response to Venetoclax and Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia: A Real‐World Study

Wei Qin, Suning Chen, Zhao Zeng, Xinyu Gao, Zhen Cheng, Suning Chen, Xuzhang Lu, Min Zhou, Rui Jiang
article en

Abstract

This retrospective study aimed to identify molecular predictors of treatment response and survival in 207 newly diagnosed acute myeloid leukemia (AML) patients treated with Venetoclax combined with hypomethylating agents (VEN-HMAs). After one treatment course, the composite complete remission (CR/CRi) rate was 69.6% (144/207), with 70.5% (93/132) of responders achieving minimal residual disease (MRD) negativity. According to the 2017 ELN risk stratification, the CR/CRi rates in the favorable-, intermediate-, and high-risk groups were 77.2%, 64.0%, and 66.6%, respectively. For treatment response, RUNX1-RUNX1T1, FLT3-ITD, and TP53 mutations independently predicted unfavorable to VEN-HMAs therapy. Multivariable analysis identified NRAS and PTPN11 mutations as independent adverse prognostic factors for overall survival, while achievement of CR/CRi after the first treatment course and receiving hematopoietic stem cell transplantation (HSCT) were favorable predictors. Based on molecular status, patients were stratified into three prognostic groups. The median OS was 9.5 months in the TP53-mutant (low-benefit) group and 21 months in the medium-benefit group (TP53 wild-type with FLT3-ITD or K/NRAS mutations). The high-benefit group (wild-type TP53, no FLT3-ITD, and wild-type K/NRAS) had a significantly superior OS (not reached) compared to the others (p < 0.001), while OS between the medium- and low-benefit groups was comparable (p = 0.096). VEN-HMAs therapy is associated with high response rates in this real-world cohort, though treatment response varies substantially by molecular profile. A comprehensive understanding of these influencing factors and the development of refined risk stratification systems require further investigation.

International Journal of Cancer
Soochow University (CN), Nanjing Traditional Chinese Medicine Hospital (CN), Changzhou No.2 People's Hospital (CN), First Affiliated Hospital of Soochow University (CN), Changzhou Third People's Hospital (CN), Nanjing Medical University (CN)
Nanjing Medical University, Changzhou Institute of Technology
Good health and well-being
Acute Myeloid Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon